McNeil willing to pay 7% royalties on ibuprofen sinus combos, minus development costs.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL WILLING TO PAY ROYALTIES ON IBUPROFEN-COUGH/COLD COMBO MINUS COST of developing the NDA for the 200 mg ibuprofen/30 mg pseudoephedrine combination in Motrin IB Sinus and Sine-Aid IB products, the J&J subsidiary said in a brief filed with the Delaware U.S. district court on May 24. Motrin IB Sinus, manufactured by McNeil, is sold by Upjohn, the other defendant in the suit.